DOI: 10.1177/02841851261489274 ISSN: 0284-1851

Could central bronchial deformity in pulmonary sarcoidosis be a sign of upper lobe fibrosis?

Sinem Ermin, Lale Duman, Seher Susam, Fatma Demirci Üçsular, Nimet Aksel, Onur Fevzi Erer
Show PDF Cite

Background

Central bronchial deformity (CBD) has been proposed as a radiological marker of a fibrotic upper-lobe phenotype in pulmonary sarcoidosis.

Purpose

To evaluate whether CBD and predefined high-resolution computed tomography (HRCT) findings at diagnosis predict the upper-lobe shrinkage (SUL) within 1 year in patients with pulmonary sarcoidosis with upper-lobe involvement.

Material and Methods

This retrospective cohort included adults with histopathologically confirmed pulmonary sarcoidosis who underwent HRCT and chest radiography at diagnosis and approximately 1 year later. Patients with baseline SUL were excluded. Two radiologists independently assessed CBD and predefined HRCT findings. SUL was evaluated on chest radiographs using prespecified signs of upper-lobe volume loss.

Results

Among 79 patients, baseline CBD was present in 33 (42%). Compared with patients without CBD, those with CBD were older (54 ± 12 vs. 46 ± 14 years; P  = 0.009), had greater smoking exposure (25 (12–35) vs. 15 (6–20) pack-years; P   =  0.046), more frequently received treatment (67% vs. 39%; P  = 0.029), and had lower spirometric values. Neither baseline CBD ( P  = 0.966) nor other baseline HRCT findings were associated with incident SUL. At 1 year, SUL was more frequent among patients with CBD (28% vs. 3%; P  = 0.007) and ground-glass attenuation (29% vs. 10%; P  = 0.031).

Conclusion

CBD was associated with lung remodeling and lower spirometric values but did not predict SUL within 1 year. Its associaton with SUL at 1 year suggests that CBD may be a contemporaneous marker of advanced parenchymal involvement and airway distortion rather than a short-term predictor.

More from our Archive